U.S. markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.94+1.57 (+10.21%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close15.37
Bid16.91 x 1100
Ask16.94 x 1800
Day's Range15.86 - 16.96
52 Week Range1.92 - 33.79
Avg. Volume29,025,346
Market Cap2.838B
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-1.85
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is Inovio Worth Buying During the Market Correction?
    Motley Fool

    Is Inovio Worth Buying During the Market Correction?

    Inovio Pharmaceuticals (NASDAQ: INO) has been one of 2020's hottest coronavirus vaccine stocks. At one point, it was trading 10 times higher than it began the year, due largely to the speed at which it moved its COVID-19 vaccine candidate through the development process and into phase 1 clinical trials. Now, Inovio shares are nowhere near the peak they hit in June, and the stock appears to be sliding yet again as the broader market withdraws from its summer highs.

  • Benzinga

    Return On Capital Employed Overview: Inovio Pharmaceuticals

    During Q2, Inovio Pharmaceuticals's (NASDAQ: INO) reported sales totaled $267.19 thousand. Despite a 15.17% in earnings, the company posted a loss of $29.06 million. In Q1, Inovio Pharmaceuticals brought in $1.33 million in sales but lost $25.23 million in earnings.What Is ROCE? Changes in earnings and sales indicate shifts in Inovio Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Inovio Pharmaceuticals posted an ROCE of -0.16%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on INOReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.In Inovio Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Recap Inovio Pharmaceuticals reported Q2 earnings per share at $-0.2/share, which did not meet analyst predictions of $-0.17/share.See more from Benzinga * Unusual Options Activity Insight: Inovio Pharmaceuticals * ROCE Insights For Inovio Pharmaceuticals * Unusual Options Activity Insight: Inovio Pharmaceuticals(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Yahoo Finance Video

    U.S. nears 7M coronavirus cases, big pharmaceutical companies race for a vaccine

    The U.S. is inching closer to hitting 7 million coronavirus cases as Midwest states like Wisconsin, Montana and South Dakota see an uptick. This comes as big pharmaceutical companies race to find a vaccine. Yahoo Finance's Anjalee Khemlani joins The First Trade with Alexis Christoforous and Brian Sozzi to discuss that and what pharmaceutical companies are close to reaching final stages of coronavirus vaccine trials.